Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.45 |
| ▸ | HTR7 | P34969 | 12/20 | 0.45 |
| ▸ | DRD2 | P14416 | 11/20 | 0.45 |
| ▸ | HTR1A | P08908 | 6/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393454 | 1.00 | HTR6 (0.45) | HTR6HTR7DRD2HTR1AHTR2A | |
| SCHEMBL22556771 | 0.92 | ALDH1A1 (0.42) | HTR6HTR7DRD2HTR1AHTR2A | |
| SCHEMBL29393387 | 0.92 | ALDH1A1 (0.42) | HTR6HTR7DRD2HTR1AHTR2A | |
| SCHEMBL22570711 | 0.90 | HTR6 (0.47) | HTR6HTR7DRD2HTR1AHTR2A | |
| SCHEMBL27218843 | 0.83 | HSP90AA1 (0.42) | — | |
| SCHEMBL27218737 | 0.82 | HSP90AA1 (0.41) | — | |
| SCHEMBL22556717 | 0.81 | HSP90AA1 (0.40) | — | |
| SCHEMBL29391048 | 0.81 | HSP90AA1 (0.40) | — | |
| SCHEMBL29391579 | 0.80 | HSP90AA1 (0.40) | — | |
| SCHEMBL22556838 | 0.80 | HSP90AA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232448-B1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| EP-3956323-B1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | Halo Therapeutics Ltd (GB) | 2025-03-05 | — | — | EP | disclosed |
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | Halo Therapeutics Ltd (GB) | 2024-05-16 | — | — | US | disclosed |
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4232448-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2023-08-30 | — | — | EP | disclosed |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | GBIOTECH S.À.R.L. (CH) | 2022-09-01 | — | — | US | disclosed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | disclosed |
| EP-3956323-A1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | Gbiotech S.À.R.L. (CH) | 2022-02-23 | — | — | EP | disclosed |
| WO-2020211956-A1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | GBIOTECH S.À.R.L. (CH) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211956-A1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | GBIOTECH S.À.R.L. (CH) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | FFAR1, FFAR2, FFAR3 | HTR6 1075/4885HTR7 826/4885DRD2 1736/4885 |
| US-20220274968-A1 | Oxazole And Oxadiazole Derivatives Useful As Agonists Of Free Fatty Acid Receptor 1 | FFAR2, FFAR1, FFAR3 | HTR6 1466/4885HTR7 587/4885DRD2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.